Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $217.07, for a total value of $130,242.00. Following the sale, the executive vice president now directly owns 64,281 shares of the company’s stock, valued at approximately $13,953,476.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Friday, March 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $237.68, for a total value of $142,608.00.

Penumbra Stock Up 0.2 %

Penumbra stock opened at $215.42 on Friday. The firm has a market capitalization of $8.34 billion, a P/E ratio of 93.26, a P/E/G ratio of 2.12 and a beta of 0.51. The company has a current ratio of 6.06, a quick ratio of 3.49 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a twelve month low of $180.93 and a twelve month high of $348.67. The stock’s fifty day simple moving average is $244.79 and its 200-day simple moving average is $235.32.

Penumbra (NYSE:PEN) last released its earnings results on Thursday, February 22nd. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.71 by $0.05. The firm had revenue of $284.68 million during the quarter, compared to analysts’ expectations of $286.62 million. Penumbra had a return on equity of 7.49% and a net margin of 8.59%. Penumbra’s revenue for the quarter was up 28.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.16 EPS. As a group, equities analysts expect that Penumbra, Inc. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PEN. Royal Bank of Canada restated an “outperform” rating and issued a $289.00 price objective on shares of Penumbra in a report on Friday, February 23rd. JPMorgan Chase & Co. lowered shares of Penumbra from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $284.00 to $250.00 in a report on Friday, February 23rd. Truist Financial dropped their target price on shares of Penumbra from $290.00 to $280.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Piper Sandler restated an “overweight” rating and set a $290.00 price target on shares of Penumbra in a research note on Wednesday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $284.00 price target on shares of Penumbra in a research report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Penumbra presently has a consensus rating of “Moderate Buy” and a consensus target price of $304.45.

Institutional Trading of Penumbra

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Penumbra by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,658,103 shares of the company’s stock worth $920,159,000 after acquiring an additional 58,184 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Penumbra in the 4th quarter valued at $624,000. GSA Capital Partners LLP acquired a new stake in shares of Penumbra in the 4th quarter valued at $332,000. Public Employees Retirement System of Ohio lifted its position in shares of Penumbra by 63.5% during the 4th quarter. Public Employees Retirement System of Ohio now owns 24,225 shares of the company’s stock worth $6,094,000 after purchasing an additional 9,413 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Penumbra during the fourth quarter worth $447,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.